Skip to content
OpenCapital
Get started

Amneal Pharmaceuticals, Inc. AMRX Transdermal — Net revenue

Other product segments

Subtotal dosage forms
$417.92M+1.1%
Oral solid
$171.1M-4.4%
Subtotal therapeutic classes
$133.27M+23.1%
Distribution
$89.15M-15.0%
Central nervous system
$83.38M+23.3%
Government label
$59.95M+19.6%
Injectable
$49.94M+43.5%
Other dosage forms
$46.61M-17.4%
Auto-Injector
$41.91M-13.0%
Hormonal / allergy
$35.93M+5.1%
Biosimilar
$22.3M-21.9%
Other therapeutic classes
$13.95M+115%
Oral liquid
$12.09M-48.6%
Institutional
$9.82M-10.8%
International
$5.32M+331%

Similar metrics at other companies

Travere Therapeutics, Inc. logo
TVTXTotal net product sales — Total Revenue
$124.49M+64.1%
Rhythm Pharmaceuticals, Inc. logo
RYTMProduct revenue, net — Total revenues
$60.11M+59.4%
Crinetics Pharmaceuticals logo
CRNXProduct revenue, net — Total Revenue
$10.31M—
Incyte logo
INCYNet sales — Total revenues
$1.1B+19.8%
Mirum Pharmaceuticals, Inc. logo
MIRMProduct sales, net — Product sales, net
$159.88M+43.3%
Bristol-Myers Squibb logo
BMYNet product sales — Total Revenues
$11.17B+2.6%

Other financials

Income statement

See full
Revenue$722.5M+3.9%
Gross profit$320.1M+25.1%
Operating income$141.8M+41.3%
Net income$62.3M+411%
EPS (diluted)$0.19+375%

Balance sheet

See full
Cash & equivalents$197.7M+234%
Total debt$2.6B+17.7%
Total equity-$45.4M+65.5%
Total assets$3.5B+5.2%

Cash flow

See full
Operating cash flow-$26.7M-461%
CapEx$8.2M-37.9%
Free cash flow-$34.9M-507%

Valuation

See full
Market cap$5.17B+51.0%

Profitability

See full
Gross margin38.7%+2.0pp
Operating margin14.3%+1.6pp
Net margin4%+3.6pp
FCF margin7.9%-1.0pp

Returns & leverage

See full
Return on equity-52.8%-12.7pp
Debt / equity127.9×+119×
Current ratio2.5×+1.1×

Where this comes from

Reported directly by Amneal Pharmaceuticals, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Amneal Pharmaceuticals, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Amneal Pharmaceuticals, Inc.'s transdermal — net revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Amneal Pharmaceuticals, Inc.'s transdermal — net revenue?
Amneal Pharmaceuticals, Inc. (AMRX) reported transdermal — net revenue of $73.96M in Q1 2026.
How has Amneal Pharmaceuticals, Inc.'s transdermal — net revenue changed year-over-year?
Amneal Pharmaceuticals, Inc.'s transdermal — net revenue increased by 71.8% year-over-year, from $43.06M to $73.96M.
What is the long-term trend for Amneal Pharmaceuticals, Inc.'s transdermal — net revenue?
Over 3 years (2022 to 2025), Amneal Pharmaceuticals, Inc.'s transdermal — net revenue has grown at a 16.3% compound annual growth rate (CAGR), from $119.29M to $187.51M.
What does transdermal — net revenue mean?
This metric represents the total gross sales generated from transdermal drug delivery products after accounting for returns, allowances, and rebates. It serves as a key indicator of the market demand and commercial performance for the company's specialized patch-based pharmaceutical portfolio. Monitoring this revenue stream helps investors assess the growth trajectory and competitive positioning of the company's non-oral drug delivery segment.